Need help finding what you are looking for?
Contact Us
PUBLISHER: Kalorama Information | PRODUCT CODE: 1177320
PUBLISHER: Kalorama Information | PRODUCT CODE: 1177320
The World Market for Liquid Biopsy, 2023
PUBLISHED:
PAGES: 211 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Dramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report from Kalorama assesses the Liquid Biopsy Market now and in 2027. The report can be useful for business planning, market share assessment, competitive research, and due diligence for mergers and acquisitions and other partnerships.
Liquid biopsy is gaining acceptance each year. Even through the COVID-19 pandemic, announcements of new liquid biopsy products were made and studies conducted to assess the capability of these tests in clinical diagnostics uses. While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.
This report, “The World Liquid Biopsy Market, 2023 ”, from Kalorama Information, contains up-to-date information and useful data points for business planning:
The Market for Liquid Biopsy by Region
- North America
- Europe
- Asia
- Rest of World
The Market for CTC-based Liquid Biopsy
- Growth to 2027
The Market for ctDNA-based Liquid Biopsy
- Growth to 2027
The Market for EV and Exosome-based Liquid Biopsy
- Growth to 2027
The Market for Multi-Analyte-based Liquid Biopsy
- Growth to 2027
The Market for Other Analytes Liquid Biopsy
- Growth to 2027
Liquid Biopsy Market by Type of Cancer
- Breast
- Lung
- Colorectal
- Ovarian
- Prostate
- Pan-Cancer
- Other Cancer
R&D: Selected ctDNA-based Liquid Biopsy Tests in Development
- On the Market: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
- On the Market: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021
Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:
- Early detection and diagnosis / screening
- Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
- Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
- Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
These applications, increasing acceptance, the use of liquid biopsy in combination with other technologies. This report contains market assessments for these application categories.
In addition, the report profiles key companies in the market, including:
|
|
Product Code: 22-048c
Table of Contents
Chapter One: Executive Summary
- Introduction
- Liquid Biopsy Technologies
- Industry Structure
- Liquid Biopsy Market Revenues and Forecast
- Figure 1-1: Market for Liquid Biopsy 2022-2027
- Figure 1-2: Global Liquid Biopsy Market by Geographic Region, 2022 (%)
- Table 1-1: Global Liquid Biopsy Market by Geographic Region, 2022-2027 $(M)
Chapter Two: Liquid Biopsy Technologies
- Introduction
- Table 2-1: Comparison of Tissue and Liquid Biopsy
- Current Major Liquid Biopsy Technologies
- Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies
Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy
- Introduction
- Advantages and Limitations of ctDNA in Liquid Biopsy
- Current ctDNA-based Liquid Biopsy Tests
- Table 3-1: Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2022Company/ Country
- Biocartis
- Biocept
- Biodesix
- CellMax Life
- Circulogene
- Diacarta
- Epigenomics
- Foundation Medicine (Roche)
- Guardant Health
- Inivata (Neogenomics)
- LungLife AI
- Myriad Genetics
- NeoGenomics
- OncoDNA
- Personal Genomic Diagnostics
- QIAGEN
- Resolution Biosciences
- Roche Diagnostics
- Sysmex-Inostics
- Tempus
- ctDNA-based Liquid Biopsy Tests in Development
- Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development, 2022
- Exact Sciences
- Freenome
- GRAIL
Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy
- Introduction
- Challenges in the Development of CTC-based Liquid Biopsy Tests
- CTC-based Liquid Biopsy Tests
- Table 4-1: Selected Market-Available CTC-based Liquid Biopsy Tests, 2022
- Adaptive Biotechnologies
- ANGLE
- Biocept
- CellMax Life
- Epic Sciences
- GILUPI
- LungLife AI
- Menarini-Silicon Biosystems
- QIAGEN
- Selected CTC-based Liquid Biopsy Tests in Development
- Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2022
- Epic Sciences
- Liquid Biotech USA
Chapter Five: Extracellular Vesicles and Other Liquid Biopsy
- Introduction
- Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
- Table 5-1: Selected Market-Available Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2022
- Aspira Women's Health (formerly Vermillion)
- Biodesix
- Exosome Diagnostics
- Hologic
- MDxHealth
- Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
- Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2022
- Circulogene
- OncoCyte
- Resolution Biosciences
- VolitionRx
Chapter Six: Multi-Analyte Liquid Biopsy Tests
- Introduction
- Liquid Biopsy Tests Based on Multiple Analytes
- Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2022
- Biocept
- Biodesix
- Foundation Medicine (Roche)
- LungLife AI
- NeoGenomics
- OncoDNA
- Multiple Analyte-based Liquid Biopsy Tests in Development
- Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2022
- Exact Sciences
- Freenome
- GRAIL
- LungLife AI
Chapter Seven: Liquid Biopsy Tests for Research Use Only
- Introduction
- Liquid Biopsy Tests for Research Use Only
- Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2022
- Agena Bioscience
- DiaCarta
- Exosome Diagnostics
- Guardant Health
- Natera
- QIAGEN
Chapter Eight: Liquid Biopsy Industry Analysis
- Introduction
- Tiers of Competition
- Table 8-1: Selected Participants in the Liquid Biopsy Market, 2022
- Competitive Factors
- Significant Market Trends
- Table 8-2: Significant Trends in the Liquid Biopsy Market, 2022
- Personalized Medicine
- Increasing Global Life Expectancy
- New Liquid Biopsy Products
- Increasing Accessibility of Genetic Testing
- Regulatory Hurdles
- Third-Party Payor Coverage
- Demonstrated Clinical Utility
- Incidence Rates of Specific Cancers
- Competitors No Longer in the Liquid Biopsy Market
- Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market
Chapter Nine: Liquid Biopsy Market
- Market Overview
- Table 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2022 (%)
- Figure 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2022 (%)
- Market Forecast
- Table 9-2: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World, World ($ millions), 2022-2027
Chapter Ten: Market by Analyte
- Circulating Tumor DNA
- Market Overview
- Applications
- Technologies
- Specimens
- Revenue Forecast
- Table 10-1: Global Liquid Biopsy Market for ctDNA ($ millions), 2022-2027
- Circulating Tumor Cells
- Market Overview
- Applications
- Technologies
- Specimens
- Revenue Forecast
- Table 10-2: Global Liquid Biopsy Market for CTCs ($ millions), 2022-2027
- Extracellular Vesicles and Other Analytes
- Market Overview
- Applications
- Technologies
- Specimens
- Revenue Forecast
- Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles ($ millions), 2022-2027
- Multiple Analytes
- Market Overview
- Revenue Forecast
- Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2022-2027
Chapter Eleven: Market by Application
- Therapy Guidance and Monitoring
- Market Overview
- Revenue Forecast
- Table 11-1: Liquid Therapy for Therapy Guidance ($ millions), 2022-2027
- Diagnosis/Screening
- Market Overview
- Revenue Forecast
- Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening ($ millions), 2022-2027
- Disease Prognosis
- Market Overview
- Revenue Forecast
- Table 11-3: Global Liquid Biopsy Market for Disease Prognosis ($ millions), 2022-2027
Chapter Twelve: Market by Cancer Type
- Breast Cancer
- Market Overview
- Revenue Forecast
- Table 12-1: Global Liquid Biopsy Market for Breast Cancer ($ millions), 2022-2027
- Colorectal Cancer
- Market Overview
- Revenue Forecast
- Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer ($ millions), 2022-2027
- Lung Cancer
- Market Overview
- Revenue Forecast
- Table 12-3: Global Liquid Biopsy Market for Lung Cancer ($ millions), 2022-2027
- Ovarian Cancer
- Market Overview
- Revenue Forecast
- Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer ($ millions), 2022-2027
- Prostate Cancer
- Market Overview
- Revenue Forecast
- Table 12-5: Global Liquid Biopsy Market for Prostate Cancer ($ millions), 2022-2027
- Other Cancers
- Market Overview
- Revenue Forecast
- Table 12-6: Global Liquid Biopsy Market for Other Cancers ($ millions), 2022-2027
- Pan-Cancer Tests
- Market Overview
- Revenue Forecast
- Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing ($ millions), 2022-2027
Chapter Thirteen: Company Profiles
- Companies in the Market
- Table 13-1: Companies in the Liquid Biopsy Market
- Adaptive Biotechnologies
- Agena Bioscience, Inc.
- ANGLE, plc
- Aspira Women's Health
- Biocartis Group NV
- Biocept, Inc.
- Biodesix
- CellMax Life
- Circulogene
- DiaCarta, Inc.
- Epic Sciences
- Epigenomics AG
- Exact Sciences
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc. (Roche)
- Freenome, Inc.
- GILUPI GmbH
- GRAIL (Illumina)
- Guardant Health, Inc.
- Hologic
- LungLife AI (formerly Cynvenio Biosystems)
- Menarini-Silicon Biosystems, Spa
- Myriad Genetics, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Oncocyte Corporation
- OncoDNA S.A.
- Personal Genome Diagnostics
- QIAGEN N.V.
- Cell-free DNA Technologies
- CTC Technologies
- Exosome and miRNA Technologies
- Resolution Biosciences (Agilent)
- Roche Diagnostics
- Sysmex-Inostics, Inc.
- Tempus
- VolitionRx
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.